Plastic, Reconstructive and Aesthetic Surgeon · PhD · ISAPS Spain National Secretary · Scientific Director of the Nixarian Institute
Reviewed: April 2026
Direct answer: The Liquenia-SVF protocol (nanofat + autologous stromal vascular fraction) produces biopsy-verified histological changes: a significant reduction in stromal fibrosis, a decrease in CD3+ T-lymphocyte infiltrate, and an increase in microvessel density at 12 months. These results, published in the Aesthetic Surgery Journal by Oxford University Press (2025, DOI: 10.1093/asj/sjaf148), demonstrate true tissue regeneration in 18 women with moderate-to-severe vulvar lichen sclerosus who had not responded to corticosteroids. A single session. 12-month follow-up.
If you have vulvar lichen sclerosus, you have probably heard that it “has no cure” and that the only option is corticosteroid creams. What perhaps no one has explained is that there is published scientific evidence from 2022 and 2025 that shows, with real biopsies, what happens inside your vulvar tissue after treatment with your own regenerative cells.
This article is not a testimonial or a promise. It is an accessible-language translation of the histological and immunohistochemical results of a clinical study published in the Aesthetic Surgery Journal (Oxford University Press), conducted by Dr. Patricia Gutiérrez-Ontalvilla and her team at the Nixarian Institute in Valencia. The study included 18 patients with moderate-to-severe vulvar lichen sclerosus and a 12-month follow-up—data you can verify yourself.
If you have ever wondered, “Does the treatment really change anything in my tissue, or does it only relieve symptoms temporarily?”, this article has a clear answer.
Why the biopsy is the only argument that cannot be refuted
Symptoms are subjective: itching may decrease, and the skin may feel more elastic. But a biopsy does not lie. It is a snapshot of a real tissue sample, analysed by specialists at an independent pathology laboratory under a light microscope at 200× magnification and using immunohistochemistry techniques.
In the study published in 2025 (DOI: 10.1093/asj/sjaf148), biopsies were taken immediately before treatment and 12 months after a single session of the Liquenia-SVF protocol. The samples assessed: epithelial thickness, basal vacuolisation, stromal hyalinisation, inflammatory infiltrate density, and microvascular density, as well as immunohistochemical markers for CD3+ and CD8+ T lymphocytes.
What was found was not merely symptom relief. It was measurable tissue regeneration.
What the biopsy shows before treatment: the real damage of lichen sclerosus
The pre-treatment biopsies from the 18 patients included in the study showed the classic findings of active, advanced vulvar lichen sclerosus:
- Severe epithelial atrophy: the protective layer of vulvar skin was very thin, fragile, and unable to regenerate.
- Prominent basal vacuolisation: the cells in the basal layer were damaged, with vacuoles—“bubbles”—indicating active cell destruction.
- Stromal hyalinisation: dermal tissue had been replaced by pathological hyaline collagen, the hallmark of advanced fibrosis.
- Dense lymphocytic infiltrate: hundreds of T lymphocytes attacking the tissue—the autoimmune basis of the disease.
- Thickened and detached basement membrane: a sign of chronic structural damage.
“Pre-treatment biopsies revealed classic signs of chronic damage: epithelial atrophy, basal vacuolisation, stromal hyalinisation, and prominent inflammatory infiltration.”
— Gutiérrez-Ontalvilla et al., Aesthetic Surgery Journal, 2025
These findings are not just laboratory markers. They correspond exactly to what you feel: relentless itching, skin that tears, pain during intercourse, and dryness that does not improve with any cream.
What the biopsy shows at 12 months: what changes with the Liquenia-SVF protocol
Twelve months after a single session of the Liquenia-SVF protocol, biopsies from the same anatomical site showed:
Stromal hyalinisation: fibrosis recedes
CD3+ infiltrate: autoimmune inflammation decreases significantly
Microvascular density: new blood vessels form
Basal vacuolisation: the protective layer thickens
In several samples, complete disappearance of the hyaline stroma was documented: what used to be dense scar tissue is now functional tissue.
“Post-treatment samples showed increased epithelial thickness, reduced vacuolisation and fibrosis, and decreased presence of inflammatory cells. These changes reflect both structural regeneration and immunological modulation.”
— Gutiérrez-Ontalvilla et al., Aesthetic Surgery Journal, 2025
Important: these results demonstrate documented tissue regeneration that improves symptoms and quality of life. Vulvar lichen sclerosus remains a chronic condition (ISSVD, 2022) that requires long-term follow-up. Regeneration is not the same as a cure.
Summary table: histological changes before and after the Liquenia-SVF protocol
| Histological parameter | Pre-treatment | At 12 months |
|---|---|---|
| Stromal hyalinisation (fibrosis) | Marked | Significantly reduced |
| CD3+ T-cell infiltrate | High | Significant reduction |
| Microvascular density (vessels) | Reduced | Marked increase |
| Basal vacuolisation | Prominent | Reduced |
| Epithelial atrophy | Present | Reduced |
| Hyaline stroma (fibrosis) | Present | Absent in several samples |
| Overall inflammatory infiltrate | Dense | Markedly decreased |
Source: Gutiérrez-Ontalvilla P. et al. (2025). Clinical and Histopathological Investigation of Stromal Vascular Fraction and Nanofat in Vulvar Lichen Sclerosus. Aesthetic Surgery Journal. DOI: 10.1093/asj/sjaf148
Why corticosteroids cannot show this
The control group in the previous clinical trial (published in Aesthetic Plastic Surgery, 2022) received 0.05% clobetasol propionate for 12 months following the standard regimen. Control-group biopsies at 12 months showed:
- Persistence of dense subepithelial lymphocytic infiltrates.
- Epithelial atrophy without resolution.
- No changes in stromal fibrosis.
This does not mean corticosteroids are useless: they control symptoms and remain the first-line treatment recommended by clinical guidelines (ISAPS, ISSVD, BAD). However, they do not regenerate tissue. They do not reverse fibrosis. They do not increase vascularisation.
The difference between relieving and regenerating is exactly what separates conventional treatment from the Liquenia-SVF protocol.
Do you have lichen sclerosus and are not improving with the cream?
Request a personalised assessment of your case with Dr. Patricia Gutiérrez-Ontalvilla.
The clinical outcomes that accompany the biopsy
The histological changes did not occur in the laboratory while the patient continued to suffer. They translated into clinical and quality-of-life improvements measured with internationally validated scales:
| Validated scale | Pre-treatment | At 12 months |
|---|---|---|
| CSS Symptoms (pain, itching, burning) | 20.12 | 4.71 |
| CSS Signs (plaques, fissures, atrophy) | 5.79 | 2.00 |
| CSS Total | 25.97 | 6.71 |
| 5D Itch Scale (itching) | 6.82 | 2.35 |
| Skindex-29 (quality of life) | 42.88 | 24.82 |
Source: Gutiérrez-Ontalvilla P. et al. (2025). Aesthetic Surgery Journal. DOI: 10.1093/asj/sjaf148
What these figures mean in real life: patients went from an average symptom score of 20.12 to 4.71—a 77% reduction. Itching decreased from 6.82 to 2.35. Overall quality of life improved in a statistically significant way. And these results were maintained throughout the 12-month follow-up after a single session.
A.F., 52 years old: from white plaques to visible regeneration
The same study also clinically documents the case of a 52-year-old patient. Photographs taken before treatment showed white plaques characteristic of active vulvar lichen sclerosus. Photographs at the one-year follow-up showed:
- 100% reduction in the surface area of white plaques.
- Significant recovery of mucosal pigmentation.
- No recurrence at 12 months after a single session.
This is the same patient documented in the Aesthetic Surgery Journal publication (2025), Figure 7. It is not an anonymous testimonial on the internet. It is a patient with biopsy and photographic follow-up in an indexed scientific journal.
“I was one of those women who had spent years applying cream without anything truly changing. When Dr. Gutiérrez explained to me that the biopsy showed a real reduction in inflammation and tissue regeneration, for the first time I felt that someone was treating the disease and not just masking the itching.”
— A.F., 52 years old, treated in 2024 at the Nixarian Institute, Valencia.
Does this treatment also work for vulvar lichen planus?
The Liquenia-SVF protocol was initially developed for vulvar lichen sclerosus, the most common inflammatory vulvar dermatosis. However, the biological basis of the treatment—adipose-derived regenerative cells with anti-inflammatory and immunoregulatory properties—is also relevant for vulvar lichen planus, another autoimmune dermatosis with partially shared mechanisms.
Each case—both vulvar lichen sclerosus and vulvar lichen planus—is assessed individually in consultation, depending on the clinical stage and response to previous treatments.
Download the scientific guide to the Liquenia-SVF protocol — data, biopsies, and FAQs.
Frequently asked questions about biopsy and regenerative cell treatment for vulvar lichen sclerosus
Does a lichen sclerosus biopsy hurt?
The diagnostic biopsy (4–6 mm punch) is performed under local anaesthesia in the clinic. Discomfort is minimal and short-lived. In the Liquenia-SVF protocol, biopsies are taken before and after treatment to objectively document histological changes.
How long does it take to see the effect of regenerative cell treatment in lichen sclerosus?
According to data published in 2025, symptom improvement begins from the first month. Most patients notice perceptible changes between the second and third month. Biopsies at 12 months confirm that the reduction in fibrosis and inflammation, and the increase in vascularisation, are maintained and continue to progress throughout the year of follow-up.
Is it necessary to repeat the Liquenia-SVF treatment?
At the Nixarian Institute, individualised follow-up has been carried out for 10 years. Of the patients from the first studies, only one has required a booster session. The vast majority have maintained results with a single session of the Liquenia-SVF protocol.
Can the treatment be done if I have been using clobetasol for years?
Yes. Patients stop using ultra-potent topical corticosteroids one month before treatment so as not to interfere with the baseline biopsy. The study’s inclusion criteria specifically include patients with at least 3 months of prior topical treatment without a satisfactory response.
Is the Liquenia-SVF protocol endorsed by international clinical guidelines?
Yes. In 2025, Dr. Patricia Gutiérrez-Ontalvilla co-signed the ISAPS (International Society of Aesthetic Plastic Surgery) clinical practice guideline on regenerative management of vulvar lichen sclerosus, published in Aesthetic Plastic Surgery (DOI: 10.1007/s00266-025-05459-7). It is the first international guideline to include stromal vascular fraction as a therapeutic option.
Scientific References
- Gutiérrez-Ontalvilla P, et al. Clinical and Histopathological Investigation of Stromal Vascular Fraction and Nanofat in Vulvar Lichen Sclerosus. Aesthetic Surgery Journal. 2025. DOI: 10.1093/asj/sjaf148
- Gutiérrez-Ontalvilla P, et al. Autologous Fat Grafting and SVF in Vulvar Lichen Sclerosus. Aesthetic Plastic Surgery. 2022.
- ISAPS Clinical Practice Guideline: Regenerative Management of Vulvar Lichen Sclerosus. Aesthetic Plastic Surgery. 2025. DOI: 10.1007/s00266-025-05459-7
- Lewis FM, et al. British Association of Dermatologists guidelines for the management of lichen sclerosus. Br J Dermatol. 2018.
- ISSVD Consensus Statement on Lichen Sclerosus. 2022.
About the Author
Dr. Patricia Gutiérrez-Ontalvilla is a plastic, reconstructive and aesthetic surgeon, holds a PhD in Medicine (cum laude), and is ISAPS National Secretary for Spain. She leads the Nixarian Institute in Valencia, where she developed the Liquenia-SVF protocol for the treatment of vulvar lichen sclerosus. She is the lead author of the study published in the Aesthetic Surgery Journal (2025) and co-author of the ISAPS clinical practice guideline (2025) on regenerative management of lichen sclerosus. President of the Nixarian Foundation. Full professional profile →
Take the first step
If your vulvar lichen sclerosus does not respond to corticosteroids and you would like to know whether you are a candidate for the Liquenia-SVF protocol, request a personalised assessment.
